Evaluation of a highly sensitive qualitative human immunodeficiency virus type 1 (HIV-1) RNA assay for detection of HIV-1 suppression

Journal of Clinical Microbiology

Volumn 47, Issue 3, 2009, Pages 833-836

  Nugent, C Thomas ^a   Nodelman, Vladislav ^a   Giachetti, Cristina ^a   Richman, Douglas D ^b   Looney, David J ^b  

^a Gen Probe Incorporated   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; VIRUS DETECTION; VIRUS LOAD;

HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 62749199826     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01464-08     Document Type: Article

References (15)

1. Caliendo, A. M., J. Ingersoll, A. M. Green, F. S. Nolte, and K. A. Easley. 2004. Comparison of the sensitivities and viral load values of the AMPLICOR HIV-1 MONITOR version 1.0 and 1.5 tests. J. Clin. Microbiol. 42:5392-5393.
2. Egger, M., M. May, G. Chêne, A. N. Phillips, B. Ledergerber, F. Dabis, D. Costagliola, A. D'Arminio Monforte, F. de Wolf, P. Reiss, J. D. Lundgren, A. C. Justice, S. Staszewski, C. Leport, R. S. Hogg, C. A. Sabin, M. J. Gill, B. Salzberger, J. A. Sterne, and the ART Cohort Collaboration. 2002. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 360:119-129.
3. Galli, R., L. Merrick, M. Friesenhahn, and R. Ziermann. 2005. Comprehensive comparison of the VERSANT HIV-1 RNA 3.0 (bDNA) and COBAS AMPLICOR HIV-1 MONITOR 1.5 assays on 1,000 clinical specimens. J. Clin. Virol. 34:245-252.
4. Reference deleted.
5. Havlir, D. V., R. Bassett, D. Levitan, P. Gilbert, P. Tebas, A. C. Collier, M. S. Hirsch, C. Ignacio, J. Condra, H. F. Günthard, D. D. Richman, and J. K. Wong. 2001. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 286:171-179.
6. Katsoulidou, A., E. Papachristou, M. Petrodaskalaki, V. Sypsa, C. G. Anastassopoulou, P. Gargalianos, A. Karafoulidou, M. Lazanas, T. Kordossis, A. Andoniadou, and A. Hatzakis. 2004. Comparison of three current viral load assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma. J. Virol. Methods 121:93-99.
7. Macias, J., J. C. Palomares, J. A. Mira, M. J. Torres, J. A. Garcia-Garcia, J. M. Rodriquez, S. Vergera, and J. A. Pineda. 2005. Transient rebounds of HIV plasma viremia are associated with the emergence of drug resistance mutations in patients on highly active antiretroviral therapy. J. Infect. 51:195-200.
8. Martinez-Picado, J., M. P. DePasquale, N. Kartsonis, G. J. Hanna, J. Wong, D. Finzi, E. Rosenberg, H. F. Gunthard, L. Sutton, A. Savara, C. J. Petropoulos, N. Hellmann, B. D. Walker, D. D. Richman, R. Siliciano, and R. T. D'Aquila. 2000. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl. Acad. Sci. USA 97:10948-10953.
9. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
10. Mira, J. A., J. Macías, C. Nogales, J. Fernández-Rivera, J. A. García-García, A. Ramos, and J. A. Pineda. 2002. Transient rebounds of low-level viraemia among HIV-infected patients under HAART are not associated with virological or immunological failure. Antivir. Ther. 7:251-256.
11. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Ann. Intern. Med. 126:939-945.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. 6 October 2005, posting date. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, Washington, DC. http://aidsinfo.nih.gov/contentfiles/AdultandAdolescentGL.pdf.
13. Sklar, P. A., D. J. Ward, R. K. Baker, K. C. Wood, Z. Gafoor, C. F. Alzola, A. C. Moorman, S. D. Holmberg, and the HIV Outpatient Study Investigators. 2002. Prevalence and clinical correlates of HIV viremia ("blips") in patients with previous suppression below the limits of quantification. AIDS 16:2035-2041.
14. Sungkanuparph, S., E. T. Overton, W. Seyfried, R. K. Groger, V. J. Fraser, and W. G. Powderly. 2005. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin. Infect. Dis. 41:1326-1332.
15. Vargo, J., K. Smit, C. Knott, S Wang, C. Fang, S. McDonough, C. Giachetti, S. Caglioti, R. Gammon, D. Gilbert, J. B. Jackson, W. Richards, S. Stramer, and L. Mimms. 2002. Clinical specificity and sensitivity of a blood screening assay for detection of HIV-1 and HCV RNA. Transfusion 42:876-885.